CTIS2023-507351-29-00进行中（未招募）1 期
A 52-Week, Open-Label Extension Study of ACP-204 in Adults with Alzheimer's Disease Psychosis - ACP-204-008
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 752
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Subject has successfully completed ACP-204-006 study, Male or female (age 55 to 85 years old): female must be of non-childbearing potential, male must take appropriate contraceptive method if partner has childbearing potential, Subject has a designated study partner/caregiver, Subjects are able to complete all study visits with a study partner/caregiver, Signed inform consent form with a caregiver or legal representative
排除标准
- •Requires treatment with a medication prohibited by the protocol, Is in hospice and receiving end-of-life palliative care, or has become bedridden, Female who is pregnant or breastfeeding, Unstable clinically significant medical condition other than AD, Any medical condition that in the opinion of the investigator may affect safety or ability to complete the study
研究者
相似试验
Enrolling By Invitation
3 期
ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension StudyAlzheimer's Disease PsychosisNCT06194799ACADIA Pharmaceuticals Inc.752
进行中（未招募）
1 期
A trial to see the effects of ACP-196 (the test drug) in Patients who have Waldenstrom MacroglobulinemiaWaldenström MacroglobulinemiaMedDRA version: 21.0Level: PTClassification code 10047804Term: Waldenstrom's macroglobulinaemia recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: PTClassification code 10047805Term: Waldenstrom's macroglobulinaemia refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-003212-36-NLAcerta Pharma BV88
进行中（未招募）
不适用
A Trial to See the Effects of ACP-196 (the test drug) in Patients who haveWaldenström MacroglobulinemiaEUCTR2014-003212-36-FRAcerta Pharma BV88
进行中（未招募）
不适用
An Open-label, Phase 1b/2 Study of ACP-196 in Subjectswith Waldenström MacroglobulinemiaWaldenström MacroglobulinemiaMedDRA version: 18.0Level: PTClassification code 10047804Term: Waldenstrom's macroglobulinaemia recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.0Level: PTClassification code 10047805Term: Waldenstrom's macroglobulinaemia refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-003212-36-ESAcerta Pharma BV88
已完成
2 期
An Open-label, Phase 2 Study of ACP-196 in Subjects with Waldenström MacroglobulinemiaWaldenström Macroglobulinemiamobus Waldenström10025320NL-OMON53142ACERTA PHARMA, BV7